linjc16/ctgov huggingface dataset:
A Study of the Cost for Patients Operated for Adhesive Obstruction (SBO) During a Five-year Period

Study Overview
=================
Brief Summary
-----------------
A cohort study of the cost for patients operated for adhesive small bowel obstruction (SBO) during a five-year period

Detailed Description
-----------------
It is a population-based cohort study of the costs for patients operated for adhesive small bowel obstruction during a five-year period (2007-2012) in two Swedish neighboring regions. Patients were identified by a broad search of operation and International Classification of Diseases (ICD) codes. Data regarding surgery and complications has been analyzed in a previous study (Clinical trials no NCT0353459) The costs for hospital stay, radiology, Intensive Care Unit (ICU)-care, operation for the index SBO care event were calculated. The cost for revisit, sick leave and recurrent SBO during follow-up were calculated. Patients were followed to 31st January 2017, last medical note or death.

Official Title
-----------------
A Cohort Study of the Cost for Patients Operated for Adhesive Obstruction (SBO) During a Five-year Period

Conditions
-----------------
Adhesive Small Bowel Obstruction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Above18 years of age Surgery for adhesive surgical bowel obstruction (SBO) Exclusion Criteria: • Surgery for SBO of other etiology than adhesions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cost for primary hospital admission in patients who underwent SBO surgery during 2007-2012 | Per 100 000 inhabitants and year | 2007-2012 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cost for further hospital admissions, surgery and outpatient visits during follow-up |  | 2007-2012 | 
| Potential cost-reduction with prophylactic treatment calculating with different prophylactic efficacy levels |  | 2007-2012 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cohort, Surgery, Adhesive Small Bowel Obstruction, Cost
A Retrospective Study to Evaluate the Predictability of Abnormal Arterial Blood Gas Measurements Through Novel Observations of Continuous Trends in Electronically Measured Respiratory Rate in a Mixed Cohort of Respiratory Compromised Patients

Study Overview
=================
Brief Summary
-----------------
A retrospective study to evaluate the predictability of abnormal arterial blood gas measurements through novel observations of continuous trends in electronically measured respiratory in a mixed cohort of respiratory compromised patients.

Official Title
-----------------
A Retrospective Study to Evaluate the Predictability of Abnormal Arterial Blood Gas Measurements Through Novel Observations of Continuous Trends in Electronically Measured Respiratory Rate in a Mixed Cohort of Respiratory Compromised Patients

Conditions
-----------------
Respiratory Failure, COPD, Pneumonia, Community-acquired Pneumonia, COVID-19, Pulmonary Disease

Intervention / Treatment
-----------------
* Device: RespiraSense


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Respiratory condition is the primary admission diagnosis Exclusion Criteria: Pregnant patients in their 2nd or 3rd trimester

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COPD<br>Patients admitted with COPD as the primary admission. | Device: RespiraSense<br>* The use of continuous electronic monitoring of respiratory rate<br>|
| Respiratory Compromised General<br>Patients admitted with Pneumonia, COPD, COVID, to be included | Device: RespiraSense<br>* The use of continuous electronic monitoring of respiratory rate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Positive Predictive Value/Precision (PPV) | Positive Predictive Value/Precision (PPV) of an elevated RespiraSense monitoring Respiratory Rate (RR) for an abnormal ABG - for a single disease state (COPD) | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PPV of an elevated RR for an abnormal ABG - for a mix of disease states | PPV of an elevated RR for an abnormal ABG - for a mix of disease states, all of which fall under Respiratory Failure | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Respiratory Rate, Arterial Blood Gas
Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center

Study Overview
=================
Brief Summary
-----------------
The choice of antimicrobial therapy to treat complex bone and joint infections (BJI) is challenging, requiring consideration of: (i) the problem of bone diffusion; (ii) the necessity of using antimicrobials active against bacterial biofilms; (iii) the growing incidence of antibiotic resistance; and (iv) the high risk of severe adverse events (SAE) in response to first-line antimicrobials in these patients. Consequently, off-label use of recently developed antimicrobials, such as daptomycin, is frequently required as salvage therapy in complex BJI. Even if daptomycin does not have approval for the treatment of BJI, the Infectious Diseases Society of America guidelines propose this antibiotic as alternative therapy for prosthetic joint infection. The recommended dose is 6 mg/kg/d, whereas recent data support the use of higher doses in these patients as bone penetration of daptomycin is limited. The present cohort study aimed to assess the safety and efficacy of prolonged high-dose (>6 mg/kg/d) daptomycin salvage therapy in patients with complex BJI.

Official Title
-----------------
Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center

Conditions
-----------------
Bone and Joint Infection, Treated by Daptomycin

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients having BJI treated by daptomycin at >6 mg/kg/d Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure of daptomycin through plasma concentration (Cmin) | The approximal maximal treatment duration is 300 days. Daptomycin trough plasma concentration (Cmin) is determined monthly to detect any patients with daptomycin trough levels (Cmin) over 24 mg/L. Cmin is determined 24 h after daptomycin injection (just before reinjection, if performed) using a validated HPLC process developed in the laboratory and a diode array UV detector. Cmin > 24 mg/L was considered an overdose, as the risk of high CPK levels (with or without symptoms of myopathy) is greater above this threshold | 300 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bone and Joint Infection, Daptomycin, Eosinophilic pneumonia
The Precision and Arm-to-Arm Variation of Mechanomyography and Acceleromyography for Monitoring of Neuromuscular Block

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is the examine the precision of acceleromyography and mechanomyography during recovery from a neuromuscular blocking agent and to examine whether there is any difference in monitoring block at the dominant or non-dominant arm. Our hypothesis is that there is no significant difference in neither the precision nor the level of block in the contralateral arms.

Official Title
-----------------
The Precision and Arm-to-Arm Variation og Mechanomyography and Acceleromyography for Monitoring the Neuromuscular Block During Anesthesia, A Randomized Controlled Study

Conditions
-----------------
Neuromuscular Blockade

Intervention / Treatment
-----------------
* Device: TOF-Watch SX (neuromuscular monitor)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I-III General anesthesia >1 hour Surgery in supine position w. possibility of monitoring the neuromuscular block at both arms (n. ulnaris stimulation/thumb response) Written informed content Exclusion Criteria: Neuromuscular disorders, hepatic and renal dysfunction Medication expected to interfere with the neuromuscular blocking agent Allergy to any medication used during anaesthesia Body weight less or exceeding 20% of ideal body weight Pregnancy or breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1: AMG<br> | Device: TOF-Watch SX (neuromuscular monitor)<br>* The variation between arms (dominant or non-dominant) when monitored with the same method on both arms<br>|
| 2: MMG<br> | Device: TOF-Watch SX (neuromuscular monitor)<br>* The variation between arms (dominant or non-dominant) when monitored with the same method on both arms<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Precision at the contralateral arms using the average residual coefficient of variation over subsequent linear regressions (detrending) over time |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bias and limits of agreement between control TOF, reappearance of T1, T2, T3, T4 |  |  | 
| T1 height at reappearance of T1-T4 |  |  | 
| Time to T1=25% |  |  | 
| Interval 25-75% |  |  | 
| Time to TOF 0.9 and 1.0 with and without normalization |  |  | 
| Time to stable T1 and stable TOF |  |  |
Fluoride Availability in Saliva After Use of Sodium Fluoride or Monofluorophosphate Toothpastes

Study Overview
=================
Brief Summary
-----------------
Considering the widespread use of sodium fluoride (NaF) and monofluorophosphate (MFP) based toothpastes, the present study aim to evaluate F availability in saliva after use of the top-selling Brazilian toothpastes. In a blind, crossover clinical trial study, volunteers will brush their teeth with one of the following toothpastes: 1) non-fluoride toothpaste (negative control group); 2) NaF/silica based toothpaste 3)MFP/calcium carbonate based toothpaste. After brushing, a rinse with purified water will be performed. Unstimulated saliva will be collected before and up to 60 min after brushing. Ionic fluoride and total soluble fluoride (corresponding to the sum of fluoride as ion and as MFP) will be determined after acid treatment of salivary samples to hydrolyze MFP. Fluoride will be determined using an ion selective electrode.

Official Title
-----------------
Fluoride Availability in Saliva After Use of NaF or MFP Toothpastes

Conditions
-----------------
Dental Caries

Intervention / Treatment
-----------------
* Drug: Toothpaste


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Good general health Good oral health Normal salivary flow rate Exclusion Criteria: Use of systemic drugs that reduce salivary flow rate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Non-fluoride toothpaste<br> | Drug: Toothpaste<br>* 1-min brushing with 1 g of the assigned toothpaste followed by a 10 mL purified water rinse<br>|
| Experimental: NaF/SiO2 toothpaste<br> | Drug: Toothpaste<br>* 1-min brushing with 1 g of the assigned toothpaste followed by a 10 mL purified water rinse<br>|
| Experimental: MFP/CaCO3 toothpaste<br> | Drug: Toothpaste<br>* 1-min brushing with 1 g of the assigned toothpaste followed by a 10 mL purified water rinse<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the curve of salivary fluoride concentration versus time after brushing with fluoride toothpastes |  | 60 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of MFP hydrolyzed in saliva as a function of time |  | 60 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
toothpastes, saliva, dental caries, fluoride
Mortality in Non-cystic Fibrosis Bronchiectasis

Study Overview
=================
Brief Summary
-----------------
In this study we analyzed the overall survival for all newly diagnosed patients with non-cystic fibrosis bronchiectasis from June 2006 onwards. The investigators wanted to confirm the known risk factors such as age, gender, smoking history and Pseudomonas aeruginosa and evaluate the impact on survival of etiology, number of different bacteriological species in retrospective and prospective sputa, azithromycin use and presence/development of pulmonary hypertension.

Official Title
-----------------
Mortality in Non-cystic Fibrosis Bronchiectasis: a Long-term Cohort Analysis

Conditions
-----------------
Non-cystic Fibrosis Bronchiectasis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with clinically significant and radiologically proven bronchiectasis Chest CT scan confirming the presence of bronchiectatic lesions and had symptoms of chronic productive cough Bronchiectasis was deemed to be present if there was one or more of the following criteria: a bronchoarterial ratio greater than 1, lack of tapering of the bronchi and visualization of bronchi within 1 cm of costal or paravertebral pleura or abutting the mediastinal pleura Exclusion Criteria: diagnosis of cystic fibrosis underlying tumoral problem causing the bronchiectatic lesions (postradiotherapy, secondary immunodeficiency due to chemotherapy or postinfectious due to tumoral obstruction) patients with asymptomatic traction bronchiectasis caused by interstitial lung disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival |  | 6 years 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| risk factor identification for NCFB | The investigators wanted to confirm the known risk factors such as age, gender, smoking history and Pseudomonas aeruginosa. | 6 years 4 months |
Role of Intraoperative Ultrasound in Gastrointestinal (GI) Malignancies

Study Overview
=================
Brief Summary
-----------------
Currently available investigating modalities like CT scans, MRI etc although have a high accuracy in staging of gastrointestinal(GI) tract malignancies, are not correct in all cases . The aim of this study is to assess the role of intraoperative ultrasound as a modality to increase the staging accuracy of GI tract malignancies

Conditions
-----------------
Ultrasonography, Gastrointestinal Disease, Malignancy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with GI tract malignancies Exclusion Criteria: Patients who refuse consent

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with gastrointestinal tract malignancies<br>All patients with GI tract malignancies undergoing surgery will be subjected to intraoperative ultrasound | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intraoperative ultrasound, GI tract malignancies, modality, ultrasound, staging modality
Role of Ultrasound in Diagnosis of Placenta Previa and MAP

Study Overview
=================
Brief Summary
-----------------
Placenta accreta occurs when the placental implantation is abnormal. The marked rise in incidence has been assumed the increasing prevalence of cesarean delivery in recent years.

Detailed Description
-----------------
The most accepted theory is that abnormal placentation . The most important risk factor for placenta accreta is placenta previa after a prior cesarean delivery. The first clinical manifestation of placenta accreta is usually severe , life-threatening hemorrhage. The recommended intervention of suspected placenta accreta is planned preterm cesarean hysterectomy with the placenta left in situ.

Official Title
-----------------
Evaluation of Role of Ultrasound TA,TV,TP in Diagnosis of Placenta Previa and MAP(Morbidly Adherent Placenta )

Conditions
-----------------
Morbidly Adherent Placenta

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant ladies with previous cesarean sections GA above 30 weeks Exclusion Criteria: Primigravida patients GA below 30 weeks

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 43 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| normal placenta<br>TA , TV ,TP us | |
| placenta previa and MAP<br>TA,TV.TP us | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of participants who will be diagnosed to have normal placenta or placenta previa or morbidly adherent placenta by US |  | within 6 weeks |
The Effect of Obstructive Sleep Apnea Treatment on Dizziness, Vertigo

Study Overview
=================
Brief Summary
-----------------
Obstructive Sleep Apnea may cause dizziness or vertigo through hypoxia of the vestibular nuclei in the brain. Treating sleep apnea may improve dizziness or vertigo.

Official Title
-----------------
The Effect of Obstructive Sleep Apnea Treatment on Dizziness, Vertigo

Conditions
-----------------
Sleep Apnea, Dizziness, Vertigo

Intervention / Treatment
-----------------
* Other: Treatment of Obstructive Sleep Apnea-CPAP/BiPAP etc./Diet/surgery/life style changes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 18 years old Diagnosed with Sleep Apnea DHI score equals or over 16 points Exclusion Criteria: Pregnant women Patients diagnosed with mental diseases Patients taking anti-vertigo medications Patients after CVA or with peripheral neuropathy Patients who suffered severe head trauma Patients with chronic renal failure Patients with malignancy at the time of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Treatment of Obstructive Sleep Apnea-CPAP/BiPAP etc./Diet/surgery/life style changes|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dizziness Handicap Inventory Score | A change in the DHI score after treatment (before treatment and after, 3 months in between) | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Romberg on foam test | A change in the time participants will stand without falling on a foam (before treatment and after, 3 months in between) | 3 months |
Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

Study Overview
=================
Brief Summary
-----------------
GL-ONC1 expanded access is for patients who are ineligible for an ongoing GL-ONC1 clinical trial. Expanded access is intended to treat individual patients with advanced stage cancers, including blood cancer, with no standard of care options for treatment. Potential patients will be evaluated individually depending on GL-ONC1 product supply.

Official Title
-----------------
Use of GL-ONC1 in Patients With Advanced Cancers With No Standard of Care

Conditions
-----------------
Advanced Stage Cancer (Solid Tumor Disease for 4 Patients), Acute Myeloid Leukemia (6 Patients)

Intervention / Treatment
-----------------
* Biological: GL-ONC1


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of advanced cancers with no standard of care option for treatment. Willing and able to provide written, signed informed consent. Use of adequate contraception. Negative pregnancy test. Exclusion Criteria: Have not recovered from severe adverse events from prior therapy. Major surgery occurred within 28 days prior to treatment. Known immune system disorders such as HIV, or active hepatitis B or C infection. Clinically significant cardiac disease (New York Heart Association Class III or IV). Have received prior therapy with an oncolytic virus of any type. Be receiving antiviral agent active against vaccinia virus (e.g., cidofovir, vaccinia immunoglobulin, imatinib, ST-246). Have known allergy to ovalbumin or other egg products. Have clinically significant dermatological disorders (e.g., eczema, psoriasis, or any unhealed skin wounds or ulcers) as assessed by the treating physician.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: GL-ONC1|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |